Company / Cash & Equivalents
Spyre Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$85.7M
FY2025
5-year range
$15.1M / $188.9M
FY2021-FY2025
Trend
-4.1%
vs FY2024
Sector context
#152 of 207
Health Care
What the data says
At $86M, Spyre Therapeutics, Inc.'s cash & equivalents ranks #152 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $13M in FY2017 to $189M in FY2023.
Based on SEC 10-K filings.
$86M in FY2025 with a 5-year CAGR of -1.0%.
Declined from $189M to $86M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +35.0%
- 5-Year CAGR
- -1.0%
- 10-Year CAGR
- -
Sector benchmark
#152 of 207 in Health CareTop 73% of 207This company $85.7M Sector average $669.5M
▼
-87.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 4.1% year-over-year.
- Ranks #152 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $85.7M | -4.1% |
| FY2024 | $89.4M | -52.7% |
| FY2023 | $188.9M | +441.8% |
| FY2022 | $34.9M | +130.2% |
| FY2021 | $15.1M | -83.2% |
| FY2020 | $90.1M | +368.0% |
| FY2019 | $19.3M | -14.3% |
| FY2018 | $22.5M | +75.2% |
| FY2017 | $12.8M | -73.2% |
| FY2016 | $47.7M | +63.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026